Evidence map›Paper›PMID 33796598›Full record

ArticleOpen forum infectious diseases2021

Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY).

Sylvain Chawki, Isabelle Charreau, Audrey Gabassi, Diane Carette, Eric Cua, Laurent Cotte, Gilles Pialoux, Claire Pintado, Laurence Meyer, Marie-Laure Chaix and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Sylvain ChawkiDepartment of Virology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID https://orcid.org/0000-0003-1656-8007
Isabelle CharreauINSERM SC10-US19, Villejuif, France.
Audrey GabassiDepartment of Virology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
Diane CaretteINSERM SC10-US19, Villejuif, France.
Eric CuaMaladies Infectieuses, Hôpital L'Archet, Nice, France.
Laurent CotteMaladies Infectieuses, Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Lyon, France.
Gilles PialouxMaladies Infectieuses, Hôpital Tenon, Assistance Publique Hôpitaux de Paris, Paris, France.
Claire PintadoMaladies Infectieuses, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France.
Laurence MeyerINSERM SC10-US19, Villejuif, France.
Marie-Laure ChaixDepartment of Virology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
Constance DelaugerreDepartment of Virology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
Jean-Michel MolinaMaladies Infectieuses, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France.
Inserm · FRAssistance Publique – Hôpitaux de Paris · FRHôpital de la Croix-Rousse · FRHôpital l'Archet · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HIV-related inflammation is associated with poor outcomes. We describe inflammatory biomarkers in 17 participants in a pre-exposure prophylaxis trial who seroconverted with very early initiation of antiretroviral therapy. Inflammation peaked at the time of HIV infection and returned to baseline within 6-12 months. Starting antiretroviral therapy very early could help mitigate long-lasting HIV-related inflammation.

Indexed as

CRPD-dimersearly antiretroviral therapyHIVIL6PrEPsCD14

Identifiers

PMID33796598
PMCPMC7990514
OpenAlexW3136891927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.